Recursion Pharmaceuticals, Inc.RXRXNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+144.3%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
+144.3%/yr
Quarterly compound
Percentile
P100
Near historical high
vs 3Y Ago
14.6x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 37.09% |
| Q3 2025 | 2.28% |
| Q2 2025 | 7.91% |
| Q1 2025 | -4.14% |
| Q4 2024 | -86.84% |
| Q3 2024 | 2.18% |
| Q2 2024 | -4.36% |
| Q1 2024 | 2.62% |
| Q4 2023 | 0.62% |
| Q3 2023 | -21.83% |
| Q2 2023 | -16.96% |
| Q1 2023 | -14.57% |
| Q4 2022 | 2.54% |
| Q3 2022 | 5.47% |
| Q2 2022 | -18.24% |
| Q1 2022 | 13.82% |
| Q4 2021 | -39.99% |
| Q3 2021 | -13.37% |
| Q2 2021 | -34.26% |
| Q1 2021 | -19.17% |
| Q4 2020 | -13.82% |
| Q3 2020 | -23.37% |
| Q2 2020 | 0.69% |
| Q1 2020 | 0.00% |